Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
Ticker SymbolSEER
Company nameSeer Inc
IPO dateDec 04, 2020
CEODr. Omid C. Farokhzad, M.D.
Number of employees134
Security typeOrdinary Share
Fiscal year-endDec 04
Address3800 Bridge Parkway, Suite 102
CityREDWOOD CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94065
Phone16504530000
Websitehttps://seer.bio/
Ticker SymbolSEER
IPO dateDec 04, 2020
CEODr. Omid C. Farokhzad, M.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data